EA201400970A1 - Новые композиции для лечения амиотрофического бокового склероза - Google Patents

Новые композиции для лечения амиотрофического бокового склероза

Info

Publication number
EA201400970A1
EA201400970A1 EA201400970A EA201400970A EA201400970A1 EA 201400970 A1 EA201400970 A1 EA 201400970A1 EA 201400970 A EA201400970 A EA 201400970A EA 201400970 A EA201400970 A EA 201400970A EA 201400970 A1 EA201400970 A1 EA 201400970A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
amiotrophic
new compositions
side sclerosis
sclerosis
Prior art date
Application number
EA201400970A
Other languages
English (en)
Other versions
EA031331B9 (ru
EA031331B1 (ru
Inventor
Даниель Коэн
Сергей Набирочкин
Илья Чумаков
Родольф Хадж
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/053570 external-priority patent/WO2012117076A2/en
Priority claimed from PCT/EP2012/053565 external-priority patent/WO2012117073A2/en
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201400970A1 publication Critical patent/EA201400970A1/ru
Publication of EA031331B1 publication Critical patent/EA031331B1/ru
Publication of EA031331B9 publication Critical patent/EA031331B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение имеет отношение к композициям и способам лечения амиотрофического бокового склероза. Конкретнее, настоящее изобретение имеет отношение к новым комбинированным способам лечения амиотрофического бокового склероза или родственного заболевания.
EA201400970A 2012-03-01 2013-02-28 Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания EA031331B9 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2012/053570 WO2012117076A2 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurogical disorders
PCT/EP2012/053565 WO2012117073A2 (en) 2011-03-01 2012-03-01 New compositions for treating neurological disorders
EP13706548.8A EP2819664B1 (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis
PCT/EP2013/054024 WO2013127917A1 (en) 2011-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Publications (3)

Publication Number Publication Date
EA201400970A1 true EA201400970A1 (ru) 2015-02-27
EA031331B1 EA031331B1 (ru) 2018-12-28
EA031331B9 EA031331B9 (ru) 2019-02-28

Family

ID=47754536

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400970A EA031331B9 (ru) 2012-03-01 2013-02-28 Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания

Country Status (12)

Country Link
EP (3) EP3348261B1 (ru)
JP (1) JP6158234B2 (ru)
CY (1) CY1119195T1 (ru)
EA (1) EA031331B9 (ru)
HR (1) HRP20171206T1 (ru)
HU (1) HUE034212T2 (ru)
LT (1) LT2819664T (ru)
PL (1) PL2819664T3 (ru)
PT (1) PT2819664T (ru)
RS (1) RS56175B1 (ru)
SI (1) SI2819664T1 (ru)
UA (1) UA114811C2 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055890A1 (en) * 2019-09-20 2021-03-25 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3180381B2 (ja) * 1991-08-31 2001-06-25 ウェルファイド株式会社 抗アルドステロン作用剤
SI2282778T1 (sl) * 2008-04-29 2017-07-31 Pharnext Novi terapevtski pristopi za zdravljenje Alzheimerjeve bolezni in sorodnih motenj z modulacijo angiogenezo
CN102065897B (zh) * 2008-04-29 2013-11-13 法奈科斯公司 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
SI2727588T1 (sl) * 2011-03-01 2019-03-29 Pharnext Na baklofenu in akamprosatu temelječa terapija nevroloških motenj
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Also Published As

Publication number Publication date
JP2015508797A (ja) 2015-03-23
UA114811C2 (uk) 2017-08-10
JP6158234B2 (ja) 2017-07-05
CY1119195T1 (el) 2018-02-14
EP2819664A1 (en) 2015-01-07
RS56175B1 (sr) 2017-11-30
PT2819664T (pt) 2017-08-24
EP3235498A1 (en) 2017-10-25
SI2819664T1 (sl) 2017-12-29
EP3348261A1 (en) 2018-07-18
EP3348261B1 (en) 2020-10-21
HUE034212T2 (en) 2018-02-28
PL2819664T3 (pl) 2017-12-29
EA031331B9 (ru) 2019-02-28
EP2819664B1 (en) 2017-05-31
EA031331B1 (ru) 2018-12-28
HRP20171206T1 (hr) 2017-10-20
LT2819664T (lt) 2017-10-25

Similar Documents

Publication Publication Date Title
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
PH12015502075B1 (en) Treatment of cataplexy
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX2013015158A (es) Compuestos inhibidores de metaloenzima.
EA201391248A1 (ru) Биспецифические связывающие агенты
EA201592157A1 (ru) Низкомолекулярные ингибиторы фиброза
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201590270A1 (ru) Применение биотина для лечения рассеянного склероза
MX2013006875A (es) Anticuepos anti-notch1.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201201296A1 (ru) Способы лечения диабетических язв стопы
EA201491500A1 (ru) Способы лечения фиброза
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU